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INTRODUCTION
Exciting or demanding biomedical investigations may attract a specific subgroup of volunteers and conclusions derived from such research may present serious limitations (Gustavsson et al., 1997) . Referral questions, motivation and ability to consent may induce selection bias of patients consenting to participate in psychiatric neurobiological research. Moreover many of such studies are based on relatively small number of participants. This might contribute to the lack of consensus between studies and affect findings' generalisation. Selection bias may thus fuel the so-called "replicability crisis" (Barch and Yarkoni, 2013; Gorgolewski and Poldrack, 2016; Tackett et al., 2016) .
A study investigating the willingness to take part in research consecutively to psychiatric admission reported high (>70%) readiness to participate, and found that rather than remuneration or other factors, altruistic motivations such as the wish to help science to progress and to allow patients to benefit from better treatments were the most frequent (Zullino et al., 2003) . Selection bias is difficult to investigate because data on patients who did not participate are typically not available. Data stemming from prospective clinical cohort studies can offer a context where such a limitation may be overcome. The goal of our study was to compare the characteristics, within a clinical cohort of patients with early psychosis treated at the Treatment and early Intervention in Psychosis Program (TIPP), of patients who consented to neurobiological research with those who didn't.
METHODS

Participants
TIPP is a specialized early psychosis program at the Department of Psychiatry in Lausanne University Hospital, Switzerland. Inclusion criteria are age between 18-35, living in catchment area (population about 300'000) and meeting criteria for psychosis, as defined by the 'psychosis threshold' subscale of the Comprehensive Assessment of At Risk Mental States scale (Yung et al., 2005) . The program has been detailed elsewhere (Baumann et al., 2013) . Patients with psychosis related to intoxication/organic brain disease, IQ<70 or that have been taking antipsychotic medication for more than six months are referred to other programs. All patients treated at TIPP are fully assessed at baseline on numerous premorbid characteristics and are then assessed regularly in order to monitor outcome and adapt treatment if improvement is insufficient. Access to the clinical data was granted by the Ethics Committee of Lausanne University and consequently all patients who received treatment within this program were automatically included in this study. This allowed us to have data on all patients whether or not they participated to neurobiological studies, which was based on an informed consent procedure. As such, and considering we are the only specialised program in our catchment area, this sample is highly representative of patients with early psychosis in our region.
Clinical assessments
Detailed evaluation of past medical history, demographic characteristics, exposure to adverse life events as well as symptoms and functioning was performed by case managers (CM) and a psychologist through interviews and a structured questionnaire. At baseline and after 2, 6, 12, 18, 24, 30 and 36 months of treatment, a series of assessments focusing on symptoms and functional level were conducted. Premorbid functional level was evaluated with the Premorbid Adjustment Scale (PAS; CannonSpoor et al., 1982) . Academic, social, childhood and early-adolescence sub-scores were computed (MacBeth and Gumley, 2008) . Past history of trauma (sexual or physical abuse before age 16) was evaluated by CM over the entire program (Alameda et al., 2016) . Past diagnosis of substance abuse/dependence was rated according to DSM-IV. The Global Assessment of Functioning (GAF) and Social and Occupational Functioning Assessment Scale (SOFAS; American Psychiatric Association, 1994) were used to assess the functional level at baseline. While GAF includes the intensity of symptoms, SOFAS only focus on social and occupational level. The lowest SOFAS and GAF scores before presentation were also estimated. Insight into illness was evaluated as complete, partial or absent (Conus et al., 2007) .
Severity of illness at baseline was assessed with the Clinical global impression scale (CGI; Guy, 1976) .
Psychopathology and functional level were scored at each assessment, with SOFAS, GAF, the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) and the Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979 ).
This study is based on the prospective follow-up of the first 284 patients who were treated within TIPP.
Participants consenting to a biomarker study
In the frame of a discussion with the CM in charge of the patient, a biomarker study was proposed to each patient during the first months following their entry in TIPP. The delay for presenting the study was justified by the wish to prioritize clinical intervention and treatment during the acute phase of psychosis when patients typically present inability to provide informed consent. The biological assessments are part of a project focusing on the identification of neurobiological markers in the early phase of psychosis (hereafter, biomarker study; e.g. Fournier et al., 2014) . Beyond psychopathology, these assessments include neuropsychological tests, genetic, biochemical and metabolomics analysis of blood and skin derived fibroblasts, multimodal magnetic resonance imaging (structural MRI, fMRI and diffusion spectrum imaging, magnetic resonance spectroscopy) and EEG. Patients included in the biomarker study provided fully informed consent, and all procedures were approved by the Local Ethics Committee.
Patients could also agree to participate to only a subset of tests of the full battery. As acknowledgment a symbolic financial compensation (from 30 to a maximum of 130 CHF for each visit depending on the number of tests) was proposed.
Statistical analysis
Comparisons between groups were performed with independent t-tests for continuous variables and Pearson's Chi-Square tests (or Fisher Exact tests) for categorical variables. Because of the longitudinal nature of some of the data, models were estimated in the multilevel framework.
Mixed effects models repeated measures analysis of variance (MMRM) was used to determine group differences over time for the different measures. Time was introduced as a "within-group" factor and participation as a "between-groups" factor. From the model, the main effects for participation and time can be examined as well as their interaction. The selection of the optimal within subject covariance matrix in each MMRM model was determined with the AIC coefficient.
Unstructured, autoregressive, compound symmetric and Toeplitz structures were tested.
Because the homogeneity of variances across occasions may not hold, we also included heterogeneous versions of these structures.
RESULTS
Out of 284 patients, 95 (33.45%) consented to the biomarker study and 189 (66.55%) didn't.
Sociodemographic and clinical data
Participants who were included in the biomarkers study differed from other patients on a small number of variables ( p=.006, mean difference = -5.68; 36 months: p=.041, mean difference = -4.39) revealed higher SOFAS scores in patients included in the biomarker study, contributing to the overall group difference (Figure 1) . Comparison of the rate of improvement between baseline and all endpoints revealed no significant differences.
DISCUSSION
Globally, our results suggest that, in our cohort, patients included in a biomarker study were globally representative of all patients treated in our program and that our results can reasonably be generalized to other patients with early psychosis. While this need to be replicated in other samples, this observation is important when considering the important role translational research may play in advancing our understanding of the basic mechanisms linked to severe mental disorders. However, the few differences identified may deserve attention and should be systematically evaluated in future studies.
The relatively high rate of consent to the biomarker study (close to 35%) is probably linked to the role played by case managers who establish a trusting relationship with patients, considering that, according to Zullino et al. (2003) , patients rely greatly on their treating team to make a decision in this regard.
While baseline and premorbid characteristics were similar in both groups, they differed in two domains. First, patients who refused the biomarker study were more likely to have had a history of offences. This is in line with Keks et al. (1991) who reported that patients refusing a neuroendocrine study were more likely to display hostility. It is likely that young patients who had to deal with the judiciary system would be less trusting of any form of institution and hence less likely to trust clinicians and researchers. This is in line with the observation that patients with early psychosis who have a forensic history are more likely to disengage from treatment (Conus et al., 2010) . Second, patients who consented to the biomarker study were more likely to have a lifetime history and/or current substance abuse comorbidity. This finding raises the ethical issue of the role played by the financial compensation that we provided and the possibility it contributed to the perpetuation of substance abuse and this needs to be further explored. However, the observation by Zullino et al. (2003) that financial compensation was rarely mentioned by patients as an argument neither to agree (23%) nor to refuse (7%) participation to research may temper this concern. Considering the impact of cannabis and other substances on neuro-biological processes (for example see Rigucci et al., 2017) as well as the impact of substance abuse discontinuation on outcome (Lambert et al., 2005; Schoeler et al., 2016) , it is very important to assess this variable in such studies.
The analysis of clinical data revealed there were no differences between groups regarding symptoms and GAF scores at baseline and during the study, showing that patients who consented to the biomarker research were not less ill than those who refused. Although the difference we observed on the SOFAS rating during the second half of the treatment phase was statistically significant, its effect size was negligible, and rate of change between both groups were not different.
Conclusion
Our study showed that, although it implied an important number of assessments, patients of our cohort who participated to our biomarker study were globally representative of patients in the entire cohort. While this needs to be replicated in other samples and the few differences identified should be systematically evaluated in future studies, this suggests that findings from neurobiological studies are likely to have a good validity and can be generalised to other patients with early psychosis. 
